114 related articles for article (PubMed ID: 15128420)
1. Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications.
Musolino C; Alonci A; Bellomo G; Loteta B; Quartarone E; Gangemi D; Massara E; Calabrò L
Eur J Haematol; 2004 Jun; 72(6):416-9. PubMed ID: 15128420
[TBL] [Abstract][Full Text] [Related]
2. Differential levels of soluble angiopoietin-2 and Tie-2 in patients with haematological malignancies.
Quartarone E; Alonci A; Allegra A; Bellomo G; Calabrò L; D'Angelo A; Del Fabro V; Grasso A; Cincotta M; Musolino C
Eur J Haematol; 2006 Dec; 77(6):480-5. PubMed ID: 16978237
[TBL] [Abstract][Full Text] [Related]
3. Differential levels of soluble endoglin (CD105) in myeloid malignancies.
Calabrò L; Fonsatti E; Bellomo G; Alonci A; Colizzi F; Sigalotti L; Altomonte M; Musolino C; Maio M
J Cell Physiol; 2003 Feb; 194(2):171-5. PubMed ID: 12494455
[TBL] [Abstract][Full Text] [Related]
4. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients.
Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
Melanoma Res; 2006 Oct; 16(5):405-11. PubMed ID: 17013089
[TBL] [Abstract][Full Text] [Related]
5. Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia.
Brunner B; Gunsilius E; Schumacher P; Zwierzina H; Gastl G; Stauder R
J Hematother Stem Cell Res; 2002 Feb; 11(1):119-25. PubMed ID: 11847008
[TBL] [Abstract][Full Text] [Related]
6. Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression.
Molica S; Vitelli G; Levato D; Giannarelli D; Vacca A; Cuneo A; Ribatti D; Digiesi G
Eur J Haematol; 2004 Jul; 73(1):36-42. PubMed ID: 15182336
[TBL] [Abstract][Full Text] [Related]
7. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity.
Anagnostopoulos A; Eleftherakis-Papaiakovou V; Kastritis E; Tsionos K; Bamias A; Meletis J; Dimopoulos MA; Terpos E
Br J Haematol; 2007 Jun; 137(6):560-8. PubMed ID: 17451406
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in treated patients with chronic myelogenous leukemia in chronic phase.
Balleari E; Bason C; Visani G; Gobbi M; Ottaviani E; Ghio R
Haematologica; 1994; 79(1):7-12. PubMed ID: 15378942
[TBL] [Abstract][Full Text] [Related]
9. Detection of bcr-abl gene expression at a low level in blood cells of some patients with essential thrombocythemia.
Hsu HC; Tan LY; Au LC; Lee YM; Lieu CH; Tsai WH; You JY; Liu MD; Ho CK
J Lab Clin Med; 2004 Feb; 143(2):125-9. PubMed ID: 14966468
[TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.
Hentschel N; Krusch M; Kiener PA; Kolb HJ; Salih HR; Schmetzer HM
Eur J Haematol; 2006 Aug; 77(2):91-101. PubMed ID: 16800841
[TBL] [Abstract][Full Text] [Related]
12. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases.
Panteli KE; Hatzimichael EC; Bouranta PK; Katsaraki A; Seferiadis K; Stebbing J; Bourantas KL
Br J Haematol; 2005 Sep; 130(5):709-15. PubMed ID: 16115126
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
[TBL] [Abstract][Full Text] [Related]
14. [Clinico-hematological characteristics of acute transformation of chronic myeloproliferative syndromes].
Hernández JM; San Miguel JF; González M; Moraleda JM; Moro MJ; Hernández J; Cuesta B; López Borrasca A
Med Clin (Barc); 1991 Sep; 97(10):369-72. PubMed ID: 1745085
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
16. [Angiogenesis in different clinical phases of chronic myeloid leukemia].
Krasowska-Kwiecień A; Kijowski J; Łukasiewicz E; Sacha T; Foryciarz K; Majka M; Ratajczak MZ; Skotnicki AB
Przegl Lek; 2009; 66(9):471-8. PubMed ID: 21033405
[TBL] [Abstract][Full Text] [Related]
17. Increased serum angiogenin concentration in colorectal cancer is correlated with cancer progression.
Shimoyama S; Yamasaki K; Kawahara M; Kaminishi M
Clin Cancer Res; 1999 May; 5(5):1125-30. PubMed ID: 10353747
[TBL] [Abstract][Full Text] [Related]
18. [Chronic myeloid leukemia beginning as thrombocythemia. Analysis of 5 cases].
Cervantes F; Alcorta I; Bosch F; Vives-Corrons JL; Rozman C
Sangre (Barc); 1992 Feb; 37(1):1-3. PubMed ID: 1585231
[TBL] [Abstract][Full Text] [Related]
19. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
20. Telomerase activity in myelodysplastic syndromes.
Gürkan E; Tanriverdi K; Başlamişli F
Leuk Res; 2005 Oct; 29(10):1131-9. PubMed ID: 16111531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
